Lenta Ltd starts redomiciliation from the British Virgin Islands to Cyprus

January 10th, 2020

Lenta Ltd., one of the largest retail chains in Russia, announced that it has started the process of redomiciliation from the British Virgin Islands into Cyprus. On 19 December 2019, further to obtaining shareholder approval of the redomiciliation at the company’s extraordinary general meeting on 22 October 2019, the company applied to the Department of Registrar of Companies and Official Receiver for continuance of its incorporation into Cyprus.

Redomiciliation will become effective when Lenta Ltd receives a certificate of temporary registration in Cyprus, and thereafter the company will change its registered office address to 6 Karaiskaki Street, City House, 3032 Limassol, Cyprus, and will change its form to the public limited liability company incorporated under the laws of Cyprus. The company will adopt new memorandum and articles of association, will change its name to Lenta PLC and will transfer its register of shareholders from the British Virgin Islands to Cyprus. The Company’s GDRs will continue to be admitted to trading on the London Stock Exchange and the Moscow Exchange and to the Official List of the UK Financial Conduct Authority.

Also, independently of the redomiciliation, the company is planning to change the depositary appointed in connection with the company’s global depositary receipt programme from Deutsche Bank Luxembourg S.A. to its affiliate Deutsche Bank Trust Company Americas. This change of depositary shall become effective as of the earlier of the effective Date and 28 February 2020.

BVI holding extends collaboration with Canada-based NetraMark Corp

December 14th, 2019

Life sciences company Juvenescence Limited and next generation AI + health data technology company NetraMark Corp. announced the extension of their collaboration agreement to include drug repurposing and discovery.

NetraMark is a Canada-based tech venture with dedicated solutions for pharmaceutical and biotech companies. Company’s AI platform was designed to extract insights from complex patient populations for patient stratification, placebo response prediction, drug repurposing, and precision multi-target identification.

CEO of the BVI holding Dr. Greg Bailey commented: “NetraMark Corp. and Juvenescence Limited are pleased to announce the extension of their business relationship. We are very excited to extend the relationship with NetraMark beyond drug resurrection to also include drug repurposing and drug discovery to find novel drugs and drug targets relating to longevity. We see this as a novel collaboration to combine NetraMark’s diverse and unique machine learning platform with Juvenescence, as we are positioned as one of the leading drug development companies in the rapidly expanding sector focused on developing therapies to modify aging.”

Harneys received several awards at BVI Financial Services Gala

November 30th, 2019

BVI law firm Harneys was named Corporate Service Provider of the Year, Litigation Practice of the Year, and Tech Savvy Firm of the Year, at the BVI Financial Services Gala Awards Dinner which was held on 28 November 2019 to celebrate the 35th anniversary of the BVI International Business Companies Act. Also, the firm got Best Corporate Social Responsibility award, and was recognised for its lifetime service to the BVI.

Harneys BVI Managing Partner Tanya Cassie-Parker said in her comments: “Thank you BVI Financial Services Week Committee for organizing this event in recognition of those that have helped set the standard for legal and financial services in the BVI. Our award wins demonstrate the strong foundation and community ties that Harneys has in the BVI. We are proud to be the first legal practice established in the BVI, and we continue to strive for excellence and innovation in the financial services industry.”

AgeX Therapeutics and its BVI-registered investor Juvenescence Ltd. announced publication of paper on the engineering of universal cells

November 2nd, 2019

Juvenescence Ltd., BVI-registered science company developing technologies to treat aging, and AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, announced the publication of a new paper in the scientific journal Regenerative Medicine. The published paper is on the strategies of engineering of allogeneic cells to be hypoimmunogenic (universal), so as not to produce an immune response. Also, the paper presents previously unpublished observation in vivo on allogeneic human stem cells (hPSCs).

The leading author of the paper is Dr. Nafees Malik, Chief Operating Officer at AgeX and Head of Cell & Gene Therapy at Juvenescence, which is a major investor in AgeX. His co-authors on the paper are Gregory Bailey, MD, Chairman of the Board of Directors of AgeX and CEO of Juvenescence; Annalisa Jenkins, MBBS, FRCP, who serves on the Board of Directors of AgeX; and Jim Mellon, Chairman of Juvenescence.

Dr Malik said in his comments on the publication: “This is a huge area of focus for us at AgeX, via our UniverCyte technology platform. In support of our own research and as a service to the overall field, we decided to put together this paper, analyzing all the leading strategies to engineer universal cells and encapsulating them in one paper.”